Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Christina Treppendahl

Nurse Practitioner Ridgeland, MS Nurse Practitioner

NPI 1922273499 CMS profile 11120762

1000 Highland Colony Pkwy Ste 7205, Ridgeland, MS 39157

Open in the dashboard

General payments

$124,571

275 records reported · program years 2021–2023

Research payments

$56

Paid to them · 1 record reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$547,958 paid to institutions, not to them · program years 2021–2025

Through program year 2023, Christina Treppendahl of Ridgeland, MS is reported in the CMS Open Payments database as having received $124,571 across 275 general payments and $56 in research payments paid to them. Separately, studies naming them as principal investigator received $547,958 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $5,720 4
2022 General $44,631 87
2022 Research $56 1
2021 General $74,220 184

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Treppendahl
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Christina Treppendahl were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Christina Treppendahl Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $74,220 $135 $40–$426 $132
2022 $44,631 $152 $48–$470 $149
2023 $5,720 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Upsher-Smith Laboratories LLC $39,937 56 payments
  2. Lilly USA, LLC $23,357 36 payments
  3. Amgen Inc. $16,965 43 payments
  4. AbbVie, Inc. $14,944 53 payments
  5. Biohaven Pharmaceuticals, Inc. $11,732 32 payments
  6. Teva Pharmaceuticals USA, Inc. $8,527 12 payments
  7. Lundbeck LLC $4,689 10 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $2,552 4 payments
  9. Allergan Inc. $1,513 10 payments
  10. Novartis Pharmaceuticals Corporation $214 15 payments
  11. Other $140 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $93,567 65 payments
  2. Travel and Lodging $11,756 32 payments
  3. Consulting Fee $9,790 6 payments
  4. Food and Beverage $4,873 169 payments
  5. Honoraria $4,500 1 payment
  6. Grant $44 1 payment
  7. Education $42 1 payment
Products named General payments · program years 2021–2023
  1. TOSYMRA $38,497 52 payments
  2. EMGALITY $21,112 32 payments
  3. AIMOVIG $17,180 58 payments
  4. UBRELVY $15,550 27 payments
  5. NURTEC ODT $14,284 36 payments
  6. ZEMBRACE SYMTOUCH $11,154 34 payments
  7. REYVOW $9,677 19 payments
  8. AJOVY $8,527 12 payments
  9. VYEPTI $4,689 10 payments
  10. BOTOX $354 13 payments
  11. Other $637 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2023
  1. Teva Pharmaceuticals USA, Inc. $56 1 payment

Records

276 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record